For blepharospasm patients with severe dry eye symptoms, especially those with fluorescein staining in cornea, the combined treatment of BoNT-A and APP is shown to be more effective compared with using BoNT-A alone. The gene discussed is APP; the disease is benign essential blepharospasm.